Back

SGLT2i Trials: current synopsis.

28 August 2018 (10:20 - 10:30)
Organised by:
Congress Presentation Part of: The future of SGLT2 Inhibitor Cardiovascular Outcomes trials: what are we hoping to learn? Diabetes and the Heart ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Anselm Kai Gitt

Klinikum Ludwigshafen, Ludwigshafen (Germany)

3 More presentations in this session

Presentation thumbnail
Opening Remarks - The future of SGLT2 Inhibitor Cardiovascular Outcomes trials: what are we hoping to learn?
Professor L. Leiter (Toronto, CA) Doctor A. Gitt (Ludwigshafen, DE)
Presentation thumbnail
Roundtable discussion: the future of SGLT2i CVOT trials: do we need more data? What are we hoping to learn.
Professor L. Leiter (Toronto, CA) Doctor A. Gitt (Ludwigshafen, DE)
Presentation thumbnail
Closing remarks - The future of SGLT2 Inhibitor Cardiovascular Outcomes trials: what are we hoping to learn?
Professor L. Leiter (Toronto, CA) Doctor A. Gitt (Ludwigshafen, DE)

Access the full session

Session thumbnail
The future of SGLT2 Inhibitor Cardiovascular Outcomes trials: what are we hoping to learn?

The Event

Event poster

ESC Congress 2018

28 August 2018 10:20 CET
You may be interested in
thumbnail
Congress Presentation
Acute hospitalised heart failure: SGLT2 inhibitors.
26 August 2022
thumbnail
Congress Presentation
Risk of death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials: an updated meta-analysis
27 August 2021
thumbnail
Congress Session
Risk prediction and treatment: bring your crystal ball?
19 May 2025
thumbnail
Congress Presentation
Patient vascular model reveals anti-inflammatory effects of SGLT2 inhibitor by modulating endothelial-T cell crosstalk
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources